Fundraising Fox

Imcheck

acquired by Clementia

11 known investors

Find your way into Imcheck

ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation. Its programs address cancer, infectious disease, and autoimmune disease.

BiotechHealthtech

Investors · 11

Agent CapitalWaltham
Andera PartnersParis
Kurma PartnersParis · $162K – $10.8M
Pfizer Venture Investments$5M – $20M
Pureos BioventuresPfäffikon
AlexandriareportedPasadena
BpifrancereportedParis, Ile-De-France · $270K
Gimvreported · 2 sourcesAntwerp · $21M – $430M
Idinvest Partnersreported
Life Sciences PartnersreportedAmsterdam
Pfizer Venturesreported

In the news

Imcheck Therapeutics Raises 103.0M USD in Series C Funding | Seedtableseedtable.com · Jun 2022ImCheck Announces Investment by BB Pureos Bioventures to Close Series B Fundraising with Total of €54 million ($64 million): Imcheck Therapeuticsimchecktherapeutics.com · Sep 2020ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases: Imcheck Therapeuticsimchecktherapeutics.com · Dec 2019

Frequently asked questions

What does Imcheck do?
ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation. Its programs address cancer, infectious disease, and autoimmune disease.
Who are Imcheck's investors?
Imcheck's investors include Agent Capital, Andera Partners, Kurma Partners, Pfizer Venture Investments, Pureos Bioventures, Alexandria, Bpifrance, Gimv and 3 more.
Who acquired Imcheck?
Imcheck was acquired by Clementia.